scholarly journals 545 Cardioprotective effects mediated by AT1 receptor blockade and enhancing ang 1-7 in experimental heart failure in ACE2-null mice

2011 ◽  
Vol 27 (5) ◽  
pp. S258-S259 ◽  
Author(s):  
S. Bodiga ◽  
Z. JiuChang ◽  
W. Wang ◽  
R. Basu ◽  
S.K. Das ◽  
...  
Keyword(s):  
Heart Failure ◽  
At1 Receptor ◽  
Receptor Blockade ◽  
Experimental Heart Failure ◽  
Cardioprotective Effects

Leukotriene receptor blockade in experimental heart failure

1997 ◽  
Vol 197 (4) ◽  
pp. 177-187 ◽  
Author(s):  
Michael Pfeifer ◽  
Frank Muders ◽  
Andreas Luchner ◽  
Friedrich Blumberg ◽  
Günter A. J. Riegger ◽  
...  
Keyword(s):  
Heart Failure ◽  
Receptor Blockade ◽  
Experimental Heart Failure ◽  
Leukotriene Receptor

scholarly journals Anti-Remodeling Effects of Rapamycin in Experimental Heart Failure: Dose Response and Interaction with Angiotensin Receptor Blockade

PLoS ONE ◽  
2013 ◽  
Vol 8 (12) ◽  
pp. e81325 ◽  
Author(s):  
Kalkidan Bishu ◽  
Ozgur Ogut ◽  
Sudhir Kushwaha ◽  
Selma F. Mohammed ◽  
Tomohito Ohtani ◽  
...  
Keyword(s):  
Heart Failure ◽  
Dose Response ◽  
Receptor Blockade ◽  
Angiotensin Receptor ◽  
Experimental Heart Failure ◽  
Angiotensin Receptor Blockade

Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure

2001 ◽  
Vol 101 (6) ◽  
pp. 559-566 ◽  
Author(s):  
J. C. VAILE ◽  
S. CHOWDHARY ◽  
F. OSMAN ◽  
H. F. ROSS ◽  
J. FLETCHER ◽  
...  
Keyword(s):  
Heart Failure ◽  
Blood Pressure ◽  
Heart Rate ◽  
Heart Rate Variability ◽  
Angiotensin Ii ◽  
Baroreflex Sensitivity ◽  
At1 Receptor ◽  
Receptor Blockade ◽  
Double Blind ◽  
Rr Interval

The objective of the present study was to determine the autonomic effects of angiotensin II (AT1) receptor blocker therapy in heart failure. In a randomized double-blind cross-over study, we compared the effects of candesartan and placebo on baroreflex sensitivity and on heart rate variability at rest, during stress and during 24h monitoring. Acute effects were assessed 4h after oral candesartan (8mg) and chronic effects after 4 weeks of treatment (dose titrated to 16mg daily). The study group comprised 21 patients with heart failure [mean (S.E.M.) ejection fraction 33% (1%)], in the absence of angiotensin-converting enzyme (ACE) inhibitor therapy. We found that acute candesartan was not different from placebo in its effects on blood pressure or mean RR interval. Chronic candesartan significantly reduced blood pressure [placebo, 137 (3)/82 (3)mmHg; candesartan, 121 (4)/75 (2)mmHg; P<0.001; values are mean (S.E.M.)], but had no effect on mean RR interval [placebo, 857 (25)ms; candesartan, 857 (21)ms]. Compared with placebo there were no significant effects of acute or chronic candesartan on heart rate variability in the time domain and no consistent effects in the frequency domain. Baroreflex sensitivity assessed by the phenylephrine bolus method was significantly increased after chronic candesartan [placebo, 3.5 (0.5)ms/mmHg; candesartan, 4.8 (0.7)ms/mmHg; P<0.05], although there were no changes in cross-spectral baroreflex sensitivity. Thus, in contrast with previous results with ACE inhibitors, angiotensin II receptor blockade in heart failure did not increase heart rate variability, and there was no consistent effect on baroreflex sensitivity.

Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure

2001 ◽  
Vol 101 (6) ◽  
pp. 559 ◽  
Author(s):  
J.C. VAILE ◽  
S. CHOWDHARY ◽  
F. OSMAN ◽  
H.F. ROSS ◽  
J. FLETCHER ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
At1 Receptor ◽  
Receptor Blockade ◽  
Vagal Control ◽  
Cardiac Vagal Control
Sign in / Sign up

Export Citation Format

Share Document